body weight

Novo Nordisk A/S Wegovy® showed an average 22.6% weight loss for premenopausal women with obesity, with more than…

Novo Nordisk A/S Wegovy® showed an average 22.6% weight loss for premenopausal women with obesity, with more than…

Novo Nordisk (NYSE:NVO) unveiled new clinical data on Tuesday showing that a higher 7.2 mg dose of Wegovy…

Novo Nordisk A/S Wegovy® showed an average 22.6% weight loss for premenopausal women with obesity, with more than…

Novo Nordisk A/S Early responders (15% or more weight loss after 24 weeks) to the higher dose of…

Novo Nordisk A/S Early responders (15% or more weight loss after 24 weeks) to the higher dose of…

Novo Nordisk A/S Early responders (15% or more weight loss after 24 weeks) to the higher dose of…

The U.S. Food and Drug Administration has approved a new dose of the GLP-1 class weight loss drug…

Novo Nordisk A/S The European Commission has granted final approval of a higher 7.2 mg maintenance dose of…

Wegovy® delivered substantial weight loss in women across all menopause stages, plus heart and migraine protection, shown in new Novo Nordisk data at the European Congress on Obesity